R1 Therapeutics Completes $77.5M Series A Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Should l Buy DVA?
R1 Therapeutics announced its launch with an oversubscribed $77.5M Series A financing, along with the exclusive global license to develop and commercialize AP306 outside of Greater China from China-based Alebund Pharmaceuticals. The financing was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita, with participation from Curie.Bio, SymBiosis, and U.S. Renal Care. Proceeds from the Series A financing will fund R1's global development program of AP306 in partnership with Alebund, including a Phase 2b study planned to start later this year. AP306 is a first-in-class, pan phosphate transporter inhibitor in development as a monotherapy for the treatment of hyperphosphatemia in patients with chronic kidney disease. Whereas currently available approved phosphate lowering therapies work by inhibiting "passive" transport of phosphate through binding phosphate and other mechanisms, AP306 is distinguished as being the only agent that blocks the "active" transport of phosphate for the treatment of CKD.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DVA
Wall Street analysts forecast DVA stock price to rise
5 Analyst Rating
1 Buy
3 Hold
1 Sell
Hold
Current: 152.370
Low
144.00
Averages
162.50
High
190.00
Current: 152.370
Low
144.00
Averages
162.50
High
190.00
About DVA
DaVita Inc. is a healthcare provider focused on transforming care delivery to improve the quality of life for patients globally. The Company is a provider of kidney care services in the United States. Its United States dialysis (U.S. dialysis) and related lab services business treats patients with chronic kidney failure and end-stage kidney disease (ESKD). The Company’s robust platform delivers kidney care services and includes established nephrology and payor relationships. The Company’s international operations provide dialysis and administrative services to a total of outpatient dialysis centers. The Company’s U.S. integrated kidney care (IKC) business provides integrated care and disease management services to patients in risk-based integrated care arrangements and to additional patients in other integrated care arrangements across the United States. It also maintains a few other ancillary services and investments outside its U.S. dialysis, U.S. IKC, or international operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DaVita Highlights Progress in Value-Based Kidney Care
- Significant Investment Impact: DaVita's sustained investment in value-based kidney care has led to over $5 billion in managed medical costs, enhancing patient understanding of their conditions and enabling more proactive health decisions, thereby increasing transplant rates and clinical quality.
- CKCC Model Maturity: The Comprehensive Kidney Care Contracting (CKCC) option within CMMI shows continued year-over-year growth through 2024, indicating the effectiveness and sustainability of DaVita's value-based care model in improving patient health outcomes.
- Collaborative Care Enhancements: DaVita's value-based models foster close collaboration across care teams, allowing for earlier interventions and better treatment preparations for patients managing kidney disease, thus improving overall patient care experiences.
- Support for Long-Term Innovation: DaVita's integrated kidney care programs are demonstrating early signs of financial sustainability, emphasizing that a continued focus on kidney care can drive broader healthcare innovation, providing a blueprint for transformation across the healthcare system.
See More
DaVita Advances Value-Based Kidney Care Initiatives
- Quality Improvement: DaVita achieved a 9% increase in its Total Quality Score within the Comprehensive Kidney Care Contracting (CKCC) program, driven by enhancements in optimal treatment starts, patient engagement, and behavioral health support, significantly improving overall patient care experiences.
- Significant Shared Savings: Since the inception of the CKCC program, DaVita and its partner entities have delivered over $200 million in shared savings, reflecting successful cost control and providing funding for future investments in care innovation.
- High Performers Recognition: DaVita and its physician partners accounted for 34% of the CKCC program's High Performers Pool while representing only 28% of participants, indicating their substantial impact on driving high-quality care outcomes.
- Strengthened Long-Term Commitment: With over two decades of investment in value-based care, DaVita now manages more than $5 billion in medical costs, a commitment that not only enhances transplant rates but also fosters greater patient understanding of their health, encouraging proactive health decisions.
See More
Buffett's Successor Commits to Maintaining Berkshire's Structure
- Buffett's Successor: Greg Abel took over as chairman and CEO of Berkshire Hathaway in December 2025, committing to maintain the company's decentralized structure, thereby ensuring stability and flexibility for future operations.
- Holding Strategy Unchanged: In his letter to shareholders, Abel stated he would not make significant changes to Berkshire's key holdings, indicating continued investments in major assets like American Express and Coca-Cola to secure stable long-term returns.
- Chevron's Strong Performance: Berkshire holds a 6.5% stake in Chevron, valued at approximately $24.7 billion, and with oil prices rising, Chevron's stock has surged nearly 25% in recent months, which will further enhance Berkshire's investment returns.
- DaVita's Potential: Despite facing challenges with flat customer volumes and rising costs, DaVita's projected adjusted earnings for 2026 are between $13.60 and $15 per share, and if growth materializes, DaVita's valuation could rise, positioning it as a dark horse in long-term investments.
See More
Buffett's Successor Commits to Stability at Berkshire Hathaway
- Buffett's Successor: Greg Abel took over as chairman and CEO of Berkshire Hathaway in December 2025, committing to maintaining the company's decentralized structure, thereby ensuring stability and flexibility for future operations.
- Chevron's Investment Potential: Berkshire holds a 6.5% stake in Chevron, valued at approximately $24.7 billion, and with Chevron's shares soaring nearly 25% amid rising oil prices, the company's profitability is expected to significantly enhance Berkshire's investment portfolio.
- Domino's Market Performance: Domino's trades at around 21 times forward earnings, which is on the higher end for fast-food stocks, but its consistent same-store sales growth could elevate its valuation to levels comparable to Yum! Brands and McDonald's, providing long-term compounding returns for investors.
- DaVita's Recovery Potential: Despite an 11.7% decline in earnings last year, DaVita's fourth-quarter results exceeded Wall Street estimates, with promising guidance for 2026 suggesting adjusted earnings between $13.60 and $15 per share, indicating potential for a valuation increase if earnings recover.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Healthcare Stocks Lag Amid War Jitters; DaVita Leads Ratings
- Healthcare Sector Pullback: Healthcare services and providers have traded defensively over the past week due to Iran-related war jitters, with the flagship Health Care Select Sector SPDR ETF (XLV) declining approximately 4.5% over five trading days, indicating a cautious market sentiment towards risk assets.
- DaVita's Strong Position: Among large-cap healthcare stocks, DaVita Inc. (DVA) stands out with a Strong Buy rating of 4.81, making it the only stock in the list with such a rating, which highlights its relative strength in the current market environment.
- Other Stock Ratings: Following DaVita, CVS Health Corporation (CVS) and Quest Diagnostics Incorporated (DGX) hold ratings of 3.32 and 3.26 respectively, both classified as Hold, reflecting a cautious outlook that may impact their future investment appeal.
- Rating System Overview: Seeking Alpha's Quant Ratings assess stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with scores ranging from 1 to 5, where ratings above 3.5 are considered bullish and below 2.5 bearish, illustrating the mixed sentiment within the healthcare sector.
See More
DaVita Highlights Progress in Value-Based Kidney Care
- Significant Investment Impact: DaVita's sustained investment in value-based kidney care has led to over $5 billion in managed medical costs, enhancing patient understanding of their conditions and enabling more proactive health decisions, thereby increasing transplant rates and clinical quality.
- CKCC Model Maturity: The Comprehensive Kidney Care Contracting (CKCC) option within CMMI shows continued year-over-year growth through 2024, indicating the effectiveness and sustainability of DaVita's value-based care model in improving patient health outcomes.
- Collaborative Care Enhancements: DaVita's value-based models foster close collaboration across care teams, allowing for earlier interventions and better treatment preparations for patients managing kidney disease, thus improving overall patient care experiences.
- Support for Long-Term Innovation: DaVita's integrated kidney care programs are demonstrating early signs of financial sustainability, emphasizing that a continued focus on kidney care can drive broader healthcare innovation, providing a blueprint for transformation across the healthcare system.
See More
DaVita Advances Value-Based Kidney Care Initiatives
- Quality Improvement: DaVita achieved a 9% increase in its Total Quality Score within the Comprehensive Kidney Care Contracting (CKCC) program, driven by enhancements in optimal treatment starts, patient engagement, and behavioral health support, significantly improving overall patient care experiences.
- Significant Shared Savings: Since the inception of the CKCC program, DaVita and its partner entities have delivered over $200 million in shared savings, reflecting successful cost control and providing funding for future investments in care innovation.
- High Performers Recognition: DaVita and its physician partners accounted for 34% of the CKCC program's High Performers Pool while representing only 28% of participants, indicating their substantial impact on driving high-quality care outcomes.
- Strengthened Long-Term Commitment: With over two decades of investment in value-based care, DaVita now manages more than $5 billion in medical costs, a commitment that not only enhances transplant rates but also fosters greater patient understanding of their health, encouraging proactive health decisions.
See More
Buffett's Successor Commits to Maintaining Berkshire's Structure
- Buffett's Successor: Greg Abel took over as chairman and CEO of Berkshire Hathaway in December 2025, committing to maintain the company's decentralized structure, thereby ensuring stability and flexibility for future operations.
- Holding Strategy Unchanged: In his letter to shareholders, Abel stated he would not make significant changes to Berkshire's key holdings, indicating continued investments in major assets like American Express and Coca-Cola to secure stable long-term returns.
- Chevron's Strong Performance: Berkshire holds a 6.5% stake in Chevron, valued at approximately $24.7 billion, and with oil prices rising, Chevron's stock has surged nearly 25% in recent months, which will further enhance Berkshire's investment returns.
- DaVita's Potential: Despite facing challenges with flat customer volumes and rising costs, DaVita's projected adjusted earnings for 2026 are between $13.60 and $15 per share, and if growth materializes, DaVita's valuation could rise, positioning it as a dark horse in long-term investments.
See More
Buffett's Successor Commits to Stability at Berkshire Hathaway
- Buffett's Successor: Greg Abel took over as chairman and CEO of Berkshire Hathaway in December 2025, committing to maintaining the company's decentralized structure, thereby ensuring stability and flexibility for future operations.
- Chevron's Investment Potential: Berkshire holds a 6.5% stake in Chevron, valued at approximately $24.7 billion, and with Chevron's shares soaring nearly 25% amid rising oil prices, the company's profitability is expected to significantly enhance Berkshire's investment portfolio.
- Domino's Market Performance: Domino's trades at around 21 times forward earnings, which is on the higher end for fast-food stocks, but its consistent same-store sales growth could elevate its valuation to levels comparable to Yum! Brands and McDonald's, providing long-term compounding returns for investors.
- DaVita's Recovery Potential: Despite an 11.7% decline in earnings last year, DaVita's fourth-quarter results exceeded Wall Street estimates, with promising guidance for 2026 suggesting adjusted earnings between $13.60 and $15 per share, indicating potential for a valuation increase if earnings recover.
See More
Vertex's Experimental Drug Trial Success Boosts Shares by 9%
- Successful Drug Trial: Vertex Pharmaceuticals' experimental drug povetacicept succeeded in a Phase 3 trial for a rare kidney condition, reducing levels of a disease marker by 52%, surpassing analyst expectations and indicating significant potential for expansion into kidney diseases.
- Positive Stock Reaction: Following the trial results, Vertex's shares rose over 9% on Tuesday, reflecting market optimism regarding the prospects of its new drug development, which could provide a new revenue stream for the company.
- Future Revenue Expectations: Analyst Carter Gould from Cantor Fitzgerald predicts that the two drugs Vertex is developing alongside povetacicept could generate over $10 billion in annual revenue, potentially rivaling the company's cystic fibrosis franchise that generated over $11 billion in sales last year.
- FDA Application Plans: Vertex plans to submit its application for povetacicept for IgAN to the U.S. FDA by the end of this month, with approval possible later this year through a priority review voucher, further solidifying the company's strategy in the kidney disease market.
See More
Healthcare Stocks Lag Amid War Jitters; DaVita Leads Ratings
- Healthcare Sector Pullback: Healthcare services and providers have traded defensively over the past week due to Iran-related war jitters, with the flagship Health Care Select Sector SPDR ETF (XLV) declining approximately 4.5% over five trading days, indicating a cautious market sentiment towards risk assets.
- DaVita's Strong Position: Among large-cap healthcare stocks, DaVita Inc. (DVA) stands out with a Strong Buy rating of 4.81, making it the only stock in the list with such a rating, which highlights its relative strength in the current market environment.
- Other Stock Ratings: Following DaVita, CVS Health Corporation (CVS) and Quest Diagnostics Incorporated (DGX) hold ratings of 3.32 and 3.26 respectively, both classified as Hold, reflecting a cautious outlook that may impact their future investment appeal.
- Rating System Overview: Seeking Alpha's Quant Ratings assess stocks based on critical metrics such as valuation, growth, stock momentum, and profitability, with scores ranging from 1 to 5, where ratings above 3.5 are considered bullish and below 2.5 bearish, illustrating the mixed sentiment within the healthcare sector.
See More
